Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction causing hyperglycemia. It is the most common type of diabetes.
A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Recent studies on metformin and age-related macular degeneration report conflicting findings: a JAMA Ophthalmology cohort found no association, while studies in Ophthalmology Retina and BMJ Open Ophthalmology found reduced odds of neovascular and intermediate AMD, respectively. All were observational.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778719 |
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD |
NOT_YET_RECRUITING | NA |
| NCT07778524 |
Alpelisib Challenge Test (ACT) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07778121 |
Screening for Obstructive Sleep Apnea in High-risk Patients in a Danish Rural Population: A Pilot Feasibility Study |
RECRUITING | NA |
| NCT07767331 |
PRODIAP - Patient-reported Outcomes in General Practice Among People With Type 2 Diabetes |
RECRUITING | NA |
| NCT07754461 |
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar |
RECRUITING | PHASE3 |
| NCT07748949 |
Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus |
RECRUITING | NA |
| NCT07747402 |
Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE4 |
| NCT07743307 |
Feasibility of a Diabetes Self-Management Program With Continuous Glucose Monitoring for Adults With Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07736040 |
The Impact of Diabetes Remission on Aging |
NOT_YET_RECRUITING | NA |
| NCT07734259 |
Voice-activated and Touchscreen-controlled Smart Speaker Intervention for Older Adults With Poorly Controlled Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
